IP Library Granted Patent US 9,327,017
Granted Patent B2
US 9,327,017 · App. 13/468,930 · Granted May 3, 2016

Leishmania-based carrier for vaccine delivery

Inventors: Kwang-Poo Chang (Kenilworth, IL); Sujoy Dutta (North Chicago, IL)
Assignee: Rosalind Franklin University of Medicine and Science
A61K39/008A61K41/0019C12N1/10A61K2039/521A61K2039/522A61K2039/523
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,327,017
App. No.
13/468,930
Granted
May 3, 2016
Kind
B2
Abstract

The present invention provides a composition for delivering a protein vaccination candidate to a mammalian subject having a Leishmania transfected for expressing a cDNA sequence for encoding the protein vaccination candidate, and the Leishmania containing a photosensitizer.

Claims (9)

1. A composition comprising:

a non-porphyric Leishmania transfected for expressing a cDNA sequence for encoding a protein vaccination candidate, the Leishmania containing a silicon-phthalocyanine or zinc-phthalocyanine photosensitizer; and

an isolated mammalian antigen presenting cell having an endocytic compartment, a mitochondrion, a plasma membrane, the non-porphric Leishmania positioned in the cell, and a MHC Class I epitope containing a fragment of the protein vaccination candidate on an outer surface of the plasma membrane.

2. The composition of claim 1 wherein the non-porhphric Leishmania having been exposed to light to photo-inactivate the Leishmania.

3. The composition of claim 1 wherein the non-porhphric Leishmania resides in the endocytic compartment of the cell.

4. The composition of claim 1 wherein the phthalocyanine is modified by a functional group selected from anilinium, pyridyloxy, axial ligands, and polyethylene glycol.

5. The composition of claim 1 wherein the photosensitizer is cationic and soluble.

6. The composition of claim 1 wherein the antigen presenting cell is a dendritic cell or a macrophage.

7. The composition of claim 1 wherein the photosensitizer is present in a concentration that is toxic to the non-porhphric Leishmania but not the mammalian cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 8, 2016
From: ROSALIND FRANKLIN UNIV OF MEDICINE & SCI
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039106/0191 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2012
From: CHANG, KWANG-POO; DUTTA, SUJOY
To: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
Reel/Frame 028688/0168 →
Continuity (2)
Provisional Application 61484549 · May 10, 2011
Related Publication 20120288524A1 · Nov 15, 2012